Alumis Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026Shareholders voted in new board members who will guide company decisions until 2029.
Company refreshed its investor materials to communicate strategy and progress to market participants.
Quarterly earnings show how the company performed in early 2026 and help investors track progress.
Positive drug trial data increases chances of FDA approval and future sales for this psoriasis treatment.
Shareholders approved the firm that checks the company's financial records for accuracy and honesty.
Annual earnings report shows overall company performance and guides expectations for the year ahead.
Stocky reads Alumis Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Alumis Inc.'s most recent tracked filing was a 8-K on 2 Jul 2026: Tananbaum, Tetrault, and Yao elected as Class II directors.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.